Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BTZO NYSEARCA:MEME OTCMKTS:PXFG NASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTZOBitzio$0.00$0.00▼$0.00$820K-0.343.39 million shs20.90 million shsMEMERoundhill MEME ETF$38.51$38.51$24.38▼$43.20$3.08M1.812,113 shsN/APXFGPhoenix Footwear Group$0.01$0.01$0.01▼$0.04$160K0.492,573 shsN/ASILOSilo Pharma$0.73-6.8%$0.60$0.41▼$3.37$3.49M0.29679,231 shs311,562 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTZOBitzio0.00%0.00%0.00%0.00%0.00%MEMERoundhill MEME ETF0.00%0.00%0.00%0.00%0.00%PXFGPhoenix Footwear Group0.00%0.00%0.00%+8.91%-63.33%SILOSilo Pharma-6.80%+8.97%+15.42%-3.19%-64.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTZOBitzioN/AN/AN/AN/AN/AN/AN/AN/AMEMERoundhill MEME ETFN/AN/AN/AN/AN/AN/AN/AN/APXFGPhoenix Footwear GroupN/AN/AN/AN/AN/AN/AN/AN/ASILOSilo Pharma0.8853 of 5 stars0.05.00.00.00.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTZOBitzio 0.00N/AN/AN/AMEMERoundhill MEME ETF 0.00N/AN/AN/APXFGPhoenix Footwear Group 0.00N/AN/AN/ASILOSilo Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTZOBitzioN/AN/AN/AN/AN/AN/AMEMERoundhill MEME ETFN/AN/AN/AN/AN/AN/APXFGPhoenix Footwear Group$17.97M0.01N/AN/AN/A∞SILOSilo Pharma$72.10K45.16N/AN/A$1.12 per share0.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTZOBitzioN/AN/A0.00N/AN/AN/AN/AN/AN/AMEMERoundhill MEME ETFN/AN/A69.43∞N/AN/AN/AN/AN/APXFGPhoenix Footwear Group-$2.68M-$0.18N/A∞N/A-14.91%N/AN/AN/ASILOSilo Pharma-$4.39M-$1.17N/A∞N/A-6,420.83%-84.88%-61.81%8/12/2025 (Estimated)Latest BTZO, SILO, MEME, and PXFG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025SILOSilo PharmaN/A-$0.23N/A-$0.23N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTZOBitzioN/AN/AN/AN/AN/AMEMERoundhill MEME ETF$0.140.36%N/AN/AN/APXFGPhoenix Footwear GroupN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTZOBitzioN/AN/AN/AMEMERoundhill MEME ETFN/AN/AN/APXFGPhoenix Footwear GroupN/AN/AN/ASILOSilo PharmaN/A4.734.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTZOBitzioN/AMEMERoundhill MEME ETFN/APXFGPhoenix Footwear GroupN/ASILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipBTZOBitzio9.50%MEMERoundhill MEME ETFN/APXFGPhoenix Footwear Group29.70%SILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTZOBitzio138.20 billionN/ANot OptionableMEMERoundhill MEME ETFN/A80,000N/ANot OptionablePXFGPhoenix Footwear Group4214.67 million10.31 millionNot OptionableSILOSilo Pharma24.48 million4.29 millionNot OptionableBTZO, SILO, MEME, and PXFG HeadlinesRecent News About These CompaniesSilo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15July 16, 2025 | globenewswire.comSilo Pharma Secures Exclusive License for CNS PeptidesJuly 10, 2025 | tipranks.comSilo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026 - NasdaqJuly 9, 2025 | nasdaq.comSilo Pharma, Inc. Plans IND Application Submission for PTSD Drug SPC-15 with Potential Phase 1 Trial in 2026July 7, 2025 | quiverquant.comQSilo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025July 7, 2025 | globenewswire.comSilo Pharma Faces Nasdaq Non-Compliance NoticeJuly 3, 2025 | msn.comSilo Pharma and Hoth Therapeutics plan joint venture for obesity treatmentJune 26, 2025 | investing.comSilo Pharma and Hoth Therapeutics to Form Joint Venture for VA-Developed Obesity Treatment - NasdaqJune 26, 2025 | nasdaq.comSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market - MorningstarJune 26, 2025 | morningstar.comMSilo Pharma Enters LOI for Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 26, 2025 | jcnnewswire.comJSilo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global MarketJune 25, 2025 | globenewswire.comHoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.June 25, 2025 | prnewswire.comSilo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | finanznachrichten.deSilo Pharma, Inc. Receives Notice of Allowance for Patent Strengthening SPC-15 Treatment for PTSDJune 11, 2025 | quiverquant.comQSilo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial NearsJune 11, 2025 | globenewswire.com16 Companies Announced A Bitcoin Treasury Last Week: ReportJune 9, 2025 | coingape.comCSilo Pharma, Inc. Approves $1 Million Bitcoin Purchase as Treasury Reserve AssetJune 7, 2025 | nasdaq.comSilo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetJune 5, 2025 | globenewswire.comSilo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War DoctrineJune 2, 2025 | newsfilecorp.comNSilo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 23, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?By Gabriel Osorio-Mazilli | July 23, 2025View What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?GameStop: Clarity Brings Renewed Confusion for Meme StockBy Thomas Hughes | July 22, 2025View GameStop: Clarity Brings Renewed Confusion for Meme Stock2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-BanBy Leo Miller | July 18, 2025View 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-BanKrispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat?By Jeffrey Neal Johnson | July 24, 2025View Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat?BTZO, SILO, MEME, and PXFG Company DescriptionsBitzio OTCMKTS:BTZOBitzio, Inc. develops and commercializes clean technologies in the areas of agriculture and lifestyle sectors. The company's portfolio of patented and patent-pending technologies include oil extraction and refining, renewable fuels and chemicals, solar energy and fuels, energy and chemical detection, wearables and consumer products, and others. It licenses technologies to the U.S. ethanol producers. The company also engages in producing and selling activewear and other apparel for women and children. In addition, it distributes Lexi Luu and E-motion branded apparel and accessories. The company was formerly known as Rocky Mountain Fudge Company, Inc. and changed its name to Bitzio, Inc. in June 2011. Bitzio, Inc. was founded in 1990 and is based in Chatsworth, California.Roundhill MEME ETF NYSEARCA:MEME$38.51 0.00 (0.00%) As of 12/15/2023The Roundhill MEME ETF (MEME) is an exchange-traded fund that is based on the Solactive Roundhill Meme Stock index. The fund tracks an equal-weighted index of 25 US-listed stocks selected baesd on a high social media activity score and high short interest percentage. MEME was launched on Dec 8, 2021 and is managed by Roundhill.Phoenix Footwear Group OTCMKTS:PXFG$0.01 0.00 (0.00%) As of 07/30/2025Phoenix Footwear Group, Inc. designs, develops, markets, and sells women's footwear primarily in the United States. The company offers its products under the Trotters and SoftWalk brand names. It distributes its products through department stores, specialty and independent retail stores, mail order catalogues, and Internet retailers, as well as directly to consumers through SoftWalkshoes.com and trotters.com Websites. Phoenix Footwear Group, Inc. was founded in 1882 and is headquartered in Carlsbad, California.Silo Pharma NASDAQ:SILO$0.73 -0.05 (-6.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.74 +0.01 (+1.50%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
